Gloucestershire Health and Care- NHS Trust logo
with you, for you
Responses > Myeloma Patients

Freedom of Information request Myeloma Patients

Response published: 22 September 2025

FOI Request

To whom it may concern, I am writing to you under the Freedom of Information Act 2000 on behalf of Myeloma UK to request the following information: 1. Is your health trust currently treating myeloma patients 2. Please list the hospitals in your board/trust that are currently treating myeloma patients. 3. Please list how many myeloma patients are being treated by your board/trust. Please break this down by hospital. 4. Is your health trust currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital. 5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015. If possible, please break this down by hospital. 6. Do you have a service level agreement or referral system in place with any other health trusts to deliver a) elranatamab or b) teclistamab to patients. If the answer this question is yes, which health boards / trusts do you have an agreement in place with. If you have any queries, please don't hesitate to contact me via e-mail. Thank you for your time and I look forward to your response.

FOI Response

Freedom of Information Request – Ref: GHC-22082025-697475

Thank you for your recent Freedom of Information request. Please find our response below.

You asked:

1. Is your health trust currently treating myeloma patients

2. Please list the hospitals in your board/trust that are currently treating myeloma patients.

3. Please list how many myeloma patients are being treated by your board/trust. Please break this down by hospital.

4. Is your health trust currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital.

5. Please list how many people have been given:

a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015. If possible, please break this down by hospital.

6. Do you have a service level agreement or referral system in place with any other health trusts to deliver?

a) elranatamab or b) teclistamab to patients. If the answer this question is yes, which health boards / trusts do you have an agreement in place with.

Our response:

Gloucestershire Health and Care NHS Foundation do not treat myeloma patients.  Please re-direct your request to Gloucestershire Hospitals NHS Foundation Trust at ghn-tr.foi@nhs.net.

Next steps:

Should you have any queries in relation to our response, please do not hesitate to contact us. If you are unhappy with the response you have received in relation to your request and wish to ask us to review our response, you should write to:

Louise Moss
Head of Legal Services / Associate Director of Corporate Governance
c/o Gloucestershire Health and Care NHS Foundation Trust
Edward Jenner Court
1010 Pioneer Avenue
Gloucester Business Park
Brockworth, GL3 4AW
E-mail: louise.moss@ghc.nhs.uk

If you are not content with the outcome of any review, you may apply directly to the Information Commissioner’s Office (ICO) for further advice/guidance. Generally, the ICO will not consider your case unless you have exhausted your enquiries with the Trust which should include considering the use of the Trust’s formal complaints procedure. The ICO can be contacted at: The Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.